Aditya Bardia, MD, MPH from Massachusetts General Hospital discusses SAR439859 Plus Palbociclib as First Line Therapy for Patients With ER(+) HER2(-) Advanced Breast Cancer (AMEERA-5).
Link to the Trial:
https://clinicaltrials.gov/ct2/show/NCT04478266
The main goal is to
To see if amcenestrant (SAR439859) in combination with palbociclib enhances progression-free survival (PFS) as compared to letrozole in combination with palbociclib in people with ER+, HER2- advanced breast cancer who haven’t had any previous systemic anticancer therapy for advanced disease.
* To compare overall survival in both treatment arms as a secondary goal.
* To compare the objective response rates in the two treatment groups.
* To see how long each treatment arm’s reaction lasted.
* To assess the rate of clinical benefit in all treatment groups.
* To assess progression-free survival when in the next line of treatment.
* To see how amcenestrant and palbociclib affect pharmacokinetics.
* To assess all care arms’ health-related quality of life.
* To compare the time it took for all treatment groups to receive their first dose of chemotherapy.
* To assess the wellbeing of all treatment groups.